Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis

A U.S. judge on Friday said two patents relating to Amgen Inc ' s blockbuster rheumatoid arthritis drug Enbrel (etanercept) were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news